Fulgent GeneticsFLGT
About: Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Employees: 1,012
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
4,613% more call options, than puts
Call options by funds: $43.5M | Put options by funds: $924K
38% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 50
25% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 24
1.38% more ownership
Funds ownership: 54.23% [Q3] → 55.61% (+1.38%) [Q4]
1% more funds holding
Funds holding: 182 [Q3] → 184 (+2) [Q4]
12% less capital invested
Capital invested by funds: $357M [Q3] → $314M (-$42.8M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for FLGT.
Financial journalist opinion









